Timing Pharmaceutical Co

Timing Pharmaceutical Co EBITDA per Share

The EBITDA per Share of Timing Pharmaceutical Co (6659.TWO) as of Oct 27, 2026 is 0.77 TWD. In the previous year, EBITDA per Share was 1.11 TWD — a change of -30.36% (lower).

EBITDA per Share

0.77TWD

YoY

-30.36%

Last updated:

EBITDA per Share of Timing Pharmaceutical Co is 2024 0.77 TWD. EBITDA per Share of Timing Pharmaceutical Co was 2023 1.11 TWD. It decreases by -30.36% lower compared to the previous year.

The Timing Pharmaceutical Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
0.95 TWD
Jan 1, 2023
1.11 TWD
Jan 1, 2024
0.77 TWD
The Timing Pharmaceutical Co EBITDA per Share history
YEAREBITDA per ShareYoY
0.77TWD-30.36%
1.11TWD+17.39%
0.95TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Timing Pharmaceutical Co Stock analysis

What does Timing Pharmaceutical Co do? Timing Pharmaceutical Co Ltd generates revenue through manufacturing concentrated Chinese medicine preparations, health foods, and traditional Chinese medicine formulations for domestic and overseas markets. The company accepts applications for licenses and permits related to Chinese medicine, food, and pharmaceutical products, and offers contract manufacturing services. Its comprehensive sales network covers Chinese medicine hospitals and major pharmacies across Taiwan, supported by a professional supply chain and service network. The firm also provides testing services and CDMO services for new pilot projects in research and development. The primary buyers of Timing Pharmaceutical's products include Chinese medicine hospitals, major pharmacies, and overseas markets. Domestic sales are facilitated through a full-fledged professional supply chain and service network, while overseas markets are served through direct exports and partnerships. The company's focus on traditional Chinese medicine and pharmaceuticals drives demand from healthcare institutions and consumers seeking natural health solutions. Timing Pharmaceutical Co Ltd invests annually in research and development for new pilot projects, which are supported by its contract research and development and manufacturing organization (CDMO) services. These services are contracted by clients seeking to develop and manufacture pharmaceutical products, including traditional Chinese medicine formulations. The company's portfolio includes concentrated Chinese medicine preparations, health foods, and traditional Chinese medicine formulations, all of which are distributed through its established network. Timing Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Timing Pharmaceutical Co stock

EBITDA per Share of Timing Pharmaceutical Co is 0.77 TWD in 2024.

EBITDA per Share of Timing Pharmaceutical Co changed from 1.11 TWD to 0.77 TWD, representing a -30.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Timing Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Timing Pharmaceutical Co

All Key Metrics — Timing Pharmaceutical Co